WuXi Biologics (Cayman) Inc.'s (HKG:2269) P/E Is On The Mark
Jan 25
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Healthcare Sector Analysis
UpdatedFeb 06, 2025
DataAggregated Company Financials
Companies199
- 7D0.5%
- 3M-7.3%
- 1Y0.1%
- YTD-1.7%
Last week, the Healthcare industry hasn't moved much but WuXi Biologics (Cayman) is up 15% in that time. In line with that, the industry has also been flat over the past 12 months. Earnings are forecast to grow by 28% annually.
Sector Valuation and Performance
Has the Hong Kong Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 07 Feb 2025 | HK$1.3t | HK$1.4t | HK$29.0b | 11.2x | 44.9x | 0.9x |
| Sun, 05 Jan 2025 | HK$1.3t | HK$1.4t | HK$28.8b | 11.4x | 45.4x | 0.9x |
| Tue, 03 Dec 2024 | HK$1.4t | HK$1.4t | HK$29.2b | 12x | 46.7x | 1x |
| Thu, 31 Oct 2024 | HK$1.4t | HK$1.4t | HK$29.5b | 12.4x | 46.6x | 0.9x |
| Sat, 28 Sep 2024 | HK$1.4t | HK$1.5t | HK$30.8b | 12.5x | 45.8x | 1x |
| Mon, 26 Aug 2024 | HK$1.2t | HK$1.4t | HK$26.5b | 10.6x | 44.9x | 0.8x |
| Wed, 24 Jul 2024 | HK$1.2t | HK$1.4t | HK$27.4b | 10.9x | 44.3x | 0.9x |
| Fri, 21 Jun 2024 | HK$1.3t | HK$1.4t | HK$28.7b | 11.2x | 44.8x | 0.9x |
| Sun, 19 May 2024 | HK$1.4t | HK$1.4t | HK$28.7b | 12.1x | 49.1x | 1x |
| Tue, 16 Apr 2024 | HK$1.3t | HK$1.4t | HK$28.4b | 11x | 44.6x | 0.9x |
| Thu, 14 Mar 2024 | HK$1.4t | HK$1.4t | HK$28.3b | 11.5x | 49.1x | 1x |
| Sat, 10 Feb 2024 | HK$1.3t | HK$1.4t | HK$25.8b | 11.4x | 49.2x | 0.9x |
| Mon, 08 Jan 2024 | HK$1.5t | HK$1.4t | HK$26.4b | 12.5x | 56.5x | 1x |
| Wed, 06 Dec 2023 | HK$1.6t | HK$1.4t | HK$26.4b | 12.5x | 60x | 1.1x |
| Fri, 03 Nov 2023 | HK$1.6t | HK$1.4t | HK$25.0b | 12.5x | 65x | 1.2x |
| Sun, 01 Oct 2023 | HK$1.6t | HK$1.4t | HK$24.6b | 12.6x | 64.9x | 1.1x |
| Tue, 29 Aug 2023 | HK$1.6t | HK$1.4t | HK$17.6b | 12.6x | 88.7x | 1.2x |
| Thu, 27 Jul 2023 | HK$1.7t | HK$1.4t | HK$2.6b | 14.1x | 672.5x | 1.3x |
| Sat, 24 Jun 2023 | HK$1.6t | HK$1.4t | HK$3.0b | 14x | 533.3x | 1.2x |
| Mon, 22 May 2023 | HK$1.8t | HK$1.4t | HK$3.3b | 15.2x | 541x | 1.3x |
| Wed, 19 Apr 2023 | HK$2.0t | HK$1.4t | HK$3.8b | 14.3x | 523.1x | 1.4x |
| Fri, 17 Mar 2023 | HK$1.9t | HK$1.3t | HK$93.6m | 14.9x | 20215.4x | 1.4x |
| Sun, 12 Feb 2023 | HK$2.0t | HK$1.4t | HK$2.2b | 15.5x | 925.1x | 1.5x |
| Tue, 10 Jan 2023 | HK$2.0t | HK$1.4t | HK$2.2b | 15.5x | 914.6x | 1.5x |
| Thu, 08 Dec 2022 | HK$1.8t | HK$1.3t | HK$2.1b | 13.5x | 881.2x | 1.4x |
| Sat, 05 Nov 2022 | HK$1.7t | HK$1.3t | HK$1.3b | 12.5x | 1286.6x | 1.3x |
| Mon, 03 Oct 2022 | HK$1.5t | HK$1.3t | HK$3.7b | 12.9x | 396.7x | 1.1x |
| Wed, 31 Aug 2022 | HK$1.7t | HK$1.3t | HK$4.8b | 14.3x | 355.2x | 1.3x |
| Fri, 29 Jul 2022 | HK$1.8t | HK$1.3t | -HK$1,028,595,521.00 | 14.2x | -1797.5x | 1.4x |
| Sun, 26 Jun 2022 | HK$1.9t | HK$1.3t | -HK$2,990,051,932.00 | 14.4x | -645.9x | 1.5x |
| Tue, 24 May 2022 | HK$1.7t | HK$1.3t | -HK$2,265,767,662.00 | 14.1x | -732.6x | 1.3x |
| Thu, 21 Apr 2022 | HK$1.7t | HK$1.4t | -HK$2,415,615,543.00 | 13.5x | -692.1x | 1.2x |
| Sat, 19 Mar 2022 | HK$1.8t | HK$1.3t | HK$10.4b | 12.9x | 171.2x | 1.3x |
| Mon, 14 Feb 2022 | HK$1.9t | HK$1.3t | HK$7.9b | 14x | 241.6x | 1.4x |
Price to Earnings Ratio
241.6x
Current Industry PE
- Investors are pessimistic on the Hong Kong Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 44.9x which is lower than its 3-year average PE of 112x.
- The 3-year average PS ratio of 1.2x is higher than the industry's current PS ratio of 0.92x.
Past Earnings Growth
- The earnings for companies in the Healthcare industry have grown 54% per year over the last three years.
- Revenues for these companies have grown 2.1% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare sector?
| HK Market | 0.88% | |
| Healthcare | 0.54% | |
| Healthtech | 5.44% | |
| Life Sciences | 5.38% | |
| Pharma | 0.18% | |
| Biotech | -0.17% | |
| Healthcare Services | -0.58% | |
| Medical Equipment | -1.27% | |
Industry PE
- Investors are most optimistic about the Medical Equipment industry which is trading above its 3-year average PE ratio.
- Analysts are expecting annual earnings growth of 43.3%, which is higher than its past year's earnings decline of 4.3% per year.
Forecasted Growth
- Analysts are most optimistic on the Medical Equipment industry, expecting annual earnings growth of 43% over the next 5 years.
- This is better than its past earnings decline of 4.3% per year.
- In contrast, the Pharma industry is expected to see its earnings grow by 11% per year over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2269 WuXi Biologics (Cayman) | HK$21.15 | 14.8% +HK$11.2b | 19.4% | PE30.8x | |
| 1801 Innovent Biologics | HK$35.80 | 8.3% +HK$4.5b | 3.2% | PS7.4x | |
| 3933 United Laboratories International Holdings | HK$13.46 | 16.6% +HK$3.5b | 83.4% | PE7.9x | |
| 6990 Sichuan Kelun-Biotech Biopharmaceutical | HK$173.10 | 8.7% +HK$3.1b | 110.8% | PS19.6x | |
| 1177 Sino Biopharmaceutical | HK$2.97 | 5.3% +HK$2.7b | -0.7% | PE23.6x |
